A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2023-01-13
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-02-18 (study day 18); relationship: not assessed
mild
assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-04-08 (study day 67); relationship: not assessed
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-07-31 (study day 181); relationship: not assessed
Data queries
No data queries.